Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiae361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal M2SR and BM2SR Vaccine Viruses Do Not Shed or Transmit in Ferrets.
Vaccines (Basel)
October 2024
FluGen, Inc., Madison, WI 53711, USA.
Background/objectives: Live influenza vaccines are considered to stimulate better overall immune responses but are associated with safety concerns regarding shedding and the potential for transmission or reassortment with wild-type influenza viruses. Intranasal M2SR and BM2SR (M2- and BM2-deficient single replication), intranasal influenza viruses, have shown promise as broadly cross-reactive next-generation influenza vaccines. The replication deficiency, shedding, and transmissibility of M2SR/BM2SR viruses were evaluated in a ferret model.
View Article and Find Full Text PDFIntranasal M2SR (M2-Deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults.
J Infect Dis
February 2025
FluGen, Inc, Madison, Wisconsin.
Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.
Lancet Infect Dis
October 2024
FluGen, Madison, WI, USA. Electronic address:
Background: Older adults (aged ≥65 years) show increased susceptibility to severe disease with influenza virus infection, accounting for 70-85% of annual influenza-related fatalities in the USA. Stimulating mucosal antibodies and T cells might enhance the low vaccine effectiveness seen in older adults for currently licensed inactivated influenza vaccines, which induce mainly serum antibodies. We aimed to evaluate the safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication (M2SR) vaccine, alone or coadministered with a licensed inactivated influenza vaccine (Fluzone High-Dose Quadrivalent; hereafter referred to as Fluzone HD), in older adults.
View Article and Find Full Text PDFMucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
Vaccine
April 2024
FluGen, Inc., Madison, WI, USA. Electronic address:
The COVID-19 pandemic has highlighted the need for mucosal vaccines as breakthrough infections, short-lived immune responses and emergence of new variants have challenged the efficacy provided by the first generation of vaccines against SARS-CoV-2 viruses. M2SR SARS-CoV-2, an M2-deleted single-replication influenza virus vector modified to encode the SARS-CoV-2 receptor binding domain, was evaluated following intranasal delivery in a hamster challenge model for protection against Wuhan SARS-CoV-2. An adjuvanted inactivated SARS-CoV-2 whole virus vaccine administered intramuscularly was also evaluated.
View Article and Find Full Text PDFIntranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants.
Vaccines (Basel)
June 2023
FluGen, Inc., 597 Science Drive, Madison, WI 53711, USA.
Article Synopsis
- - Current COVID-19 vaccines protect against hospitalization and death but struggle to prevent initial infection and transmission, with common breakthrough infections from new variants despite updated boosters.
- - Researchers developed a dual vaccine, SARS-CoV-2 M2SR, using an intranasal approach to boost mucosal immunity, showing promising results in mice with high levels of protective antibodies against both SARS-CoV-2 and influenza.
- - The M2SR vaccine demonstrated strong immune responses to the original strain and variants like Delta and Omicron, suggesting it could provide better protection against respiratory viruses compared to current vaccines.